TCM
CRL icon

TimesSquare Capital Management’s Charles River Laboratories CRL Stock Holding History

TimesSquare Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-129,208
Closed -$26.7M – 159
2024
Q2 		$26.7M Sell
129,208
-5,795
-4% -$1.31M 0.42% 96
2024
Q1 		$36.6M Buy
135,003
+103,168
+324% +$24.6M 0.53% 75
2023
Q4 		$7.53M Buy
+31,835
New +$6.26M 0.11% 143
2023
Q1 		– Sell
-29,900
Closed -$6.51M – 183
2022
Q4 		$6.51M Sell
29,900
-7,104
-19% -$1.55M 0.09% 157
2022
Q3 		$7.28M Sell
37,004
-201,200
-84% -$43.4M 0.1% 161
2022
Q2 		$51M Sell
238,204
-83,750
-26% -$20.5M 0.71% 52
2022
Q1 		$91.4M Sell
321,954
-57,250
-15% -$17.7M 1.03% 15
2021
Q4 		$143M Buy
379,204
+3,104
+0.8% +$1.21M 1.27% 9
2021
Q3 		$155M Sell
376,100
-124,600
-25% -$51.7M 1.35% 4
2021
Q2 		$185M Sell
500,700
-93,050
-16% -$31.1M 1.52% 5
2021
Q1 		$172M Sell
593,750
-215,300
-27% -$59.8M 1.47% 2
2020
Q4 		$202M Buy
809,050
+195,375
+32% +$46.5M 1.64% 2
2020
Q3 		$139M Sell
613,675
-30,135
-5% -$6.25M 1.3% 4
2020
Q2 		$112M Sell
643,810
-90,040
-12% -$14.4M 1.07% 10
2020
Q1 		$92.6M Sell
733,850
-59,925
-8% -$8.99M 1.1% 10
2019
Q4 		$121M Sell
793,775
-213,975
-21% -$29.6M 1.08% 8
2019
Q3 		$133M Buy
1,007,750
+99,900
+11% +$13.4M 1.18% 7
2019
Q2 		$129M Buy
907,850
+44,275
+5% +$6.01M 0.99% 20
2019
Q1 		$125M Sell
863,575
-163,475
-16% -$21.5M 0.97% 20
2018
Q4 		$116M Sell
1,027,050
-135,125
-12% -$16.9M 1% 17
2018
Q3 		$156M Buy
1,162,175
+152,505
+15% +$18.8M 1.04% 15
2018
Q2 		$113M Buy
1,009,670
+149,550
+17% +$16.2M 0.76% 31
2018
Q1 		$91.8M Sell
860,120
-55,480
-6% -$5.98M 0.62% 45
2017
Q4 		$100M Buy
915,600
+589,900
+181% +$64.2M 0.66% 45
2017
Q3 		$35.2M Buy
+325,700
New +$33.5M 0.24% 157

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

TimesSquare Capital Management's CRL Position: Q3 2024 in Review

TimesSquare Capital Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 129,208 shares — an estimated $26.7M sold.

TimesSquare Capital Management first reported a position in CRL in Q3 2017 and held it in 25 quarters. The position peaked at $202M in Q4 2020. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • TimesSquare Capital Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • TimesSquare Capital Management sold 129,208 Charles River Laboratories shares in Q3 2024, an estimated $26.7M.
  • TimesSquare Capital Management first reported a position in Charles River Laboratories in Q3 2017 and held it in 25 quarters.
  • TimesSquare Capital Management's Charles River Laboratories position peaked at $202M in Q4 2020.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on TimesSquare Capital Management's 13F filing for Q3 2024, filed 4 Nov 2024.